Osteopontin: Regulation in tumor metastasis

Cancer and Metastasis Reviews

Volumn 27, Issue 1, 2008, Pages 103-118

  Wai, Philip Y ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Integrin; Matrix metalloproteinase; Metastasis; Osteopontin

Indexed keywords

APC PROTEIN; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE SIALOPROTEIN; CORE BINDING FACTOR; DENTIN MATRIX PROTEIN 1; DENTIN SIALOPROTEIN; GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; HOX PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MYC PROTEIN; OSTEOPONTIN; PROTEIN P53; PROTEIN TCF 4; PROTEIN V SRC; RAS PROTEIN; REGULATOR PROTEIN; SMAD PROTEIN; STROMELYSIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; WNT PROTEIN;

APOPTOSIS; BINDING SITE; BREAST CANCER; CANCER INVASION; CANCER STAGING; CELL ADHESION; CELL MIGRATION; COLON CANCER; DNA SEQUENCE; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXTRACELLULAR MATRIX; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MUTAGENESIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TRANSCRIPTION REGULATION; UVEA MELANOMA;

HUMANS; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN;

EID: 38549097166     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9104-9     Document Type: Review

References (225)

1. Senger, D. R., Wirth, D. F., & Hynes, R. O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16(4), 885-893.
2. Fisher, L. W., Hawkins, G. R., Tuross, N., & Termine, J. D, (1987). Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. Journal of Biological Chemistry, 262(20), 9702-9708.
3. Kiefer, M. C., Bauer, D. M., & Barr, P. J. (1989). The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Research, 17(8), 3306.
4. Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W., et al. (1990). cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics, 7(4), 491-502.
5. Wrana, J. L., Zhang, Q., & Sodek, J. (1989). Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-I, osteopontin). Nucleic Acids Research, 17(23), 10119-10123.
6. Smith, J. H., & Denhardt, D. T. (1987). Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. Journal of Cellular Biochemistry, 34(1), 13-22.
7. Craig, A. M., Nemir, M., Mukherjee, B. B., Chambers, A. F., & Denhardt, D. T. (1988). Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochemical and Biophysical Research Communications, 157(1), 166-173.
8. Shiraga, H., Min, W., VanDusen, W. J., Clayman, M. D., Miner, D., Terrell, C. H., et al. (1992). Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proceedings of the National Academy of Sciences of the United States of America, 89(1), 426-430.
9. Patarca, R., Freeman, G. J., Singh, R. P., Wei, F. Y., Durfee, T., Blattner, F., et al. (1989). Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. Journal of Experimental Medicine, 170(1), 145-161.
10. Craig, A. M., & Denhardt, D. T. (1991). The murine gene encoding secreted phosphoprotein 1 (osteopontin): Promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163-171.
11. Denhardt, D. T., & Guo, X. (1993). Osteopontin: A protein with diverse functions. FASEB Journal, 7(15), 1475-1482.
12. Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., & Van de Water, L. (1994). Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Molecular Biology of the Cell, 5(5), 565-574.
13. Attur, M. G., Dave, M. N., Stuchin, S., Kowalski, A. J., Steiner, G., Abramson, S. B., et al. (2001). Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis and Rheumatism, 44(3), 578-584.
14. Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079-1086.
15. Johnson, R. J., Gordon, K. L., Giachelli, C., Kurth, T., Skelton, M. M., & Cowley, A. W. (2000). Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. Journal de L'hypertension, 18(10), 1497-1505.
16. Noble, B. S., & Reeve, J. (2000). Osteocyte function, osteocyte death and bone fracture resistance. Molecular and Cellular Endocrinology, 159(1-2), 7-13.
17. Scott, J. A., Weir, M. L., Wilson, S. M., Xuan, J. W., Chambers, A. F., & McCormack, D. G. (1998). Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology, 275(6), H2258-H2265.
18. Thomas, S. E., Lombard, I. D., Giachelli, C., Bohle, A., & Johnson, R. J. (1998). Osteopontin expression, tubulointerstitial disease, and essential hypertension. American Journal of Hypertension, 11(8), 954-961.
19. Rollo, E. E., Laskin, D. L., & Denhardt, D. T. (1996). Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. Journal of Leukocyte Biology, 60(3), 397-404.
20. Singh, K., Balligand, J. L., Fischer, T. A., Smith, T. W., & Kelly, R. A. (1995). Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. Journal of Biological Chemistry, 270(47), 28471-28478.
21. Feng, B., Rollo, E. E., & Denhardt, D. T. (1995). Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clinical & Experimental Metastasis, 13(6), 453-462.
22. Denhardt, D. T., Lopez, C. A., Rollo, E. E., Hwang, S. M., An, X. R., & Walther, S. E. (1995). Osteopontin-induced modifications of cellular functions. Annals of the New York Academy of Sciences, 760, 127-142.
23. Hwang, S. M., Wilson, P. D., Laskin, J. D., & Denhardt, D. T. (1994). Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. Journal of Cellular Physiology, 160(1), 61-68.
24. Hwang, S. M., Lopez, C. A., Heck, D. E., Gardner, C. R., Laskin, D. L., Laskin, J. D., et al. (1994). Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. Journal of Biological Chemistry, 269(1), 711-715.
25. Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S., & Yamamoto, S. (1994). Cloning and characterization of the human osteopontin gene and its promoter. Biochemical Journal, 303(1), 255-262.
26. Denhardt, D. T., & Noda, M. (1998). Osteopontin expression and function: role in bone remodeling. Journal of Cell Biology, 30-31, 92-102.
27. O'Regan, A., & Berman, J. S. (2000). Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. International Journal of Experimental Pathology, 81(6), 373-390.
28. Weber, G. F. (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochimica et Biophysica Acta, 1552(2), 61-85.
29. Fedarko, N. S., Jain, A., Karadag, A., & Fisher, L. W. (2004). Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB Journal, 18(6), 734-736.
30. Fisher, L. W., Jain, A., Tayback, M., & Fedarko, N. S. (2004). Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clinical Cancer Research, 10(24), 8501-8511.
31. Senger, D. R., Perruzzi, C. A., Gracey, C. F., Papadopoulos, A., & Tenen, D. G. (1988). Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Research, 48(20), 5770-5774.
32. Senger, D. R., Perruzzi, C. A., Papadopoulos, A., & Tenen, D. G. (1989). Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica et Biophysica Acta, 996(1-2), 43-48.
33. Bautista, D. S., Densted, T. J., Chambers, A. F., & Harris, J. F. (1996). Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. Journal of Cellular Biochemistry, 61(3), 402-409.
34. Patarca, R., Saavedra, R. A., & Cantor, H. (1993). Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Critical Reviews in Immunology, 13(3-4), 225-246.
35. Behrend, E. I., Chambers, A. F., Wilson, S. M., & Denhardt, D. T. (1993). Comparative analysis of two alternative first exons reported for the mouse osteopontin gene. Journal of Biological Chemistry, 268(15), 11172-11175.
36. Yamamoto, S., Hijiya, N., Setoguchi, M., Matsuura, K., Ishida, T., Higuchi, Y., et al. (1995). Structure of the osteopontin gene and its promoter. Annals of the New York Academy of Sciences, 760, 44-58.
37. Franzen, A., & Heinegard, D. (1985). Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochemical Journal, 232(3), 715-724.
38. Oldberg, A., Franzen, A., & Heinegard, D. (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America, 83(23), 8819-8823.
39. Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., & Ushio, Y. (1995). Expression of osteopontin in human glioma. Its correlation with the malignancy. Laboratory Investigation, 72(1), 55-63.
40. Senger, D. R., Asch, B. B., Smith, B. D., Perruzzi, C. A., & Dvorak, H. F. (1983). A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature, 302(5910), 714-715.
41. Senger, D. R., & Perruzzi, C. A. (1996). Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochimica et Biophysica Acta, 1314(1-2), 13-24.
42. Senger, D. R., & Perruzzi, C. A. (1985). Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Research, 45(11), 5818-5823.
43. Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., et al. (2000). Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science, 287(5454), 860-864.
44. Helluin, O., Chan, C., Vilaire, G., Mousa, S., DeGrado, W. F., & Bennett, J. S. (2000). The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. Journal of Biological Chemistry, 275(24), 18337-18343.
45. Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. Science, 285(5430), 1028-1032.
46. Liaw, L., Almeida, M., Hart, C. E., Schwartz, S. M., & Giachelli, C. M. (1994). Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circulation Research, 74(2), 214-224.
47. Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., & Giachelli, C. M. (1995). Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circulation Research, 77(4), 665-672.
48. Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., et al. (1995). The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. Journal of Clinical Investigation, 95(2), 713-724.
49. Yue, T. L., McKenna, P. J., Ohlstein, E. H., Farach-Carson, M. C., Butler, W. T., Johanson, K., et al. (1994). Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Experimental Cell Research, 214(2), 459-464.
50. Hu, D. D., Lin, E. C., Kovach, N. L., Hoyer, J. R., & Smith, J. W. (1995). A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. Journal of Biological Chemistry, 270(44), 26232-26238.
51. Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., et al. (1996). Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. Journal of Biological Chemistry, 271(45), 28485-28491.
52. Bayless, K. J., Meininger, G. A., Scholtz, J. M., & Davis, G. E. (1998). Osteopontin is a ligand for the alpha4beta1 integrin. Journal of Cell Science, 111(9), 1165-1174.
53. Denda, S., Reichardt, L. F., & Muller, U. (1998). Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Molecular Biology of the Cell, 9(6), 1425-1435.
54. Barry, S. T., Ludbrook, S. B., Murrison, E., & Horgan, C. M. (2000). A regulated interaction between alpha5beta1 integrin and osteopontin. Biochemical and Biophysical Research Communications, 267(3), 764-769.
55. Gerber, D. J., Pereira, P., Huang, S. Y., Pelletier, C., & Tonegawa, S. (1996). Expression of alpha v and beta 3 integrin chains on murine lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 93(25), 14698-14703.
56. Reinholt, F. P., Hultenby, K., Oldberg, A., & Heinegard, D. (1990). Osteopontin-a possible anchor of osteoclasts to bone. Proceedings of the National Academy of Sciences of the United States of America, 87(12), 4473-4475.
57. Singh, R. P., Patarca, R., Schwartz, J., Singh, P., & Cantor, H. (1990). Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. Journal of Experimental Medicine, 171(6), 1931-1942.
58. Bennett, J. S., Chan, C., Vilaire, G., Mousa, S. A., & DeGrado, W. F. (1997). Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. Journal of Biological Chemistry, 272(13), 8137-8140.
59. Denhardt, D. T., Noda, M., O,, Regan, A. W., Pavlin, D., & Berman, J. S. (2001). Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. Journal of Clinical Investigation, 107(9), 1055-1061.
60. Smith, L. L., & Giachelli, C. M. (1998). Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Experimental Cell Research, 242(1), 351-60.
61. Yasuyuki, Y., Matsuura, N., Sasaki, T., Murakami, I., Schneider, H., Higashiyama, S., et al. (1999). The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. Journal of Biological Chemistry, 274(51), 36328-36334.
62. Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., et al. (2003). Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochemical and Biophysical Research Communications, 310(1), 153-157.
63. Liapis, H., Flath, A., & Kitazawa, S. (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagnostic Molecular Pathology, 5(2), 127-135.
64. Angelucci, A., Festuccia, C., D'Andrea, G., Teti, A., & Bologna, M. (2002). Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biological Chemistry, 383(1), 229-234.
65. Furger, K. A., Allan, A. L., Wilson, S. M., Hota, C., Vantyghem, S. A., Postenka, C. O., et al. (2003). Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Molecular Cancer Research, 1(11), 810-819.
66. Senger, D. R., Ledbetter, S. R., Claffey, K. P., Papadopoulos-Sergiou, A., Peruzzi, C. A., & Detmar, M. (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. American Journal of Pathology, 149(1), 293-305.
67. Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., & Giachelli, C. M. (1998). NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Journal of Cell Biology, 141(4), 1083-1093.
68. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., et al. (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79(7), 1157-1164.
69. Arap, W., Pasqualini, R., & Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279(5349), 377-380.
70. Bayless, K. J., Salazar, R., & Davis, G. E. (2000). RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. American Journal of Pathology, 56(5), 1673-1683.
71. Engleman, V. W., Nickols, G. A., Ross, F. P., Horton, M. A., Griggs, D. W., Settle, S. L., et al. (1997). A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation, 99(9), 2284-2292.
72. Rabinowich, H., Lin, W. C., Amoscato, A., Herberman, R. B., & Whiteside, T. L. (1995). Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. Journal of Immunology, 154(3), 1124-1135.
73. Goodison, S., Urquidi, V., & Tarin, D. (1999). CD44 cell adhesion molecules. Molecular Pathology, 52(4), 189-196.
74. Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996). Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271(5248), 509-512.
75. Katagiri, Y. U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., et al. (1999). CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Research, 59(1), 219-226.
76. Rudzki, Z., & Jothy, S. (1997). CD44 and the adhesion of neoplastic cells. Molecular Pathology, 50(2), 7-71.
77. Ponta, H., Sherman, L., & Herrlich, P. A. (2003). CD44: From adhesion molecules to signaling regulators. Nature Reviews, Molecular Cell Biology, 4(1), 33-45.
78. Takahashi, K., Takahashi, F., Hirama, M., Tanabe, K. K., & Fukuchi, Y. (2003). Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer, 41(2), 145-153.
79. Asosingh, K., Gunthert, U., Bakkus, M. H., De Raeve, H., Goes, E., Van Riet, I., et al. (2000). In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Research, 60(11), 3096-3104.
80. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., et al. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65(1), 13-24.
81. Rudy, W., Hofmann, M., Schwartz-Albiez, R., Zoller, M., Heider, K. H., Ponta, H., et al. (1993). The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Research, 53(6), 1262-1268.
82. Gao, C., Guo, H., Downey, L., Marroquin, C., Wei, J., & Kuo, P. C. (2003). Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis, 24(12), 1871-1878.
83. Lin, Y. H., Huang, C. J., Chao, J. R., Chen, S. T., Lee, S. F., Yen, J. J., et al. (2000). Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Molecular and Cellular Biology, 20(8), 2734-2742.
84. Zohar, R., Cheifetz, S., McCulloch, C. A., & Sodek, J. (1998). Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. European Journal of Oral Sciences, 106(1), 401-407.
85. Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C. A., et al. (2000). Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. Journal of Cellular Physiology, 184(1), 118-130.
86. Sodek, J., Ganss, B., & McKee, M. D. (2000). Osteopontin. Critical Reviews in Oral Biology and Medicine, 11(3), 279-303.
87. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., et al. (1994). Osteopontin expression and distribution in human carcinomas. American Journal of Pathology, 145(3), 610-623.
88. Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95-100.
89. Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., et al. (1995). Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Laboratory Investigation, 72(1), 64-69.
90. Singhal, H., Bautista, D. S., Tonkin, K. S., O,, Malley, F. P., Tuck, A. B., Chambers, A. F., et al. (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research, 3(4), 605-611.
91. Tuck, A. B., O,, Malley, F. P., Singhal, H., Harris, J. F., Tonkin, K. S., Kerkvliet, N., et al. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. International Journal of Cancer, 79(5), 502-508.
92. Casson, A. G., Wilson, S. M., McCart, J. A., O'Malley, F. P., Ozcelik, H., Tsao, M. S., et al. (1997). Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. International Journal of Cancer, 72(5), 739-745.
93. Gotoh, M., Sakamoto, M., Kanetaka, K., Chuuma, M., & Hirohashi, S. (2002). Overexpression of osteopontin in hepatocellular carcinoma. Pathology International, 52(1), 19-24.
94. Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research, 7(12), 4060-4066.
95. Tuck, A. B., O,, Malley, F. P., Singhal, H., Tonkin, K. S., Harris, J. F., Bautista, D., et al. (1997). Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Archives of Pathology and Laboratory Medicine, 121(6), 578-584.
96. Tuck, A. B., Arsenault, D. M., O,, Malley, F. P., Hota, C., Ling, M. C., Wilson, S. M., et al. (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18(29), 4237-4246.
97. Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T., et al. (1998). Co-expression of osteopontin and CD44v9 in gastric cancer. International Journal of Cancer, 79(2), 127-132.
98. Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., et al. (1999). Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 160(4), 1269-1273.
99. Chambers, A. F., Wilson, S. M., Kerkvliet, N., O,, Malley, F. P., Harris, J. F., & Casson, A. G. (1996). Osteopontin expression in lung cancer. Lung Cancer, 15(3), 311-323.
100. Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J. A., Markwalder, R., Klima, I., et al. (1999). Osteopontin: Possible role in prostate cancer progression. Clinical Cancer Research, 5(8), 2271-2277.
101. Pan, H. W., Ou, Y. H., Peng, S. Y., Liu, S. H., Lai, P. L., Lee, P. H., et al. (2003). Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98(1), 119-127.
102. Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., et al. (2002). Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute, 94(7), 513-521.
103. Yeatman, T. J., & Chambers, A. F. (2003). Osteopontin and colon cancer progression. Clinical & Experimental Metastasis, 20(1), 85-90.
104. Rudland, P. S., Platt-Higgins, A., El-Tanani, M., De Silva Rudland, S., Barraclough, R., Winstanley, J. H., et al. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research, 62(12), 3417-3427.
105. Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., et al. (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56(6), 782-789.
106. Chang, Y. S., Kim, H. J., Chang, J., Ahn, C. M., Kim, S. K., & Kim, S. K. (2007). Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer, 57(3), 373-380.
107. Bramwell, V. H., Doig, G. S., Tuck, A. B., Wilson, S. M., Tonkin, K. S., et al. (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clinical Cancer Research, 12(11), 3337-3343.
108. Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., & Chambers, A. F. (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 78(3), 465-475.
109. Yoneda, T., Williams, P. J., & Niewolna, M. (1998). Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone, 23(5), 201-202.
110. Oates, A. J., Barraclough, R., & Rudland, P. S. (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13(1), 97-104.
111. Chen, H., Ke, Y., Oates, A. J., Barraclough, R., & Rudland, P. S. (1997). Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene, 14(13), 1581-1588.
112. Takahashi, F., Akutagawa, S., Fukumoto, H., Tsukiyama, S., Ohe, Y., Takahashi, K., et al. (2002). Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. International Journal of Cancer, 98(5), 707-712.
113. Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research, 58(22), 5206-5215.
114. Wu, Y., Denhardt, D. T., & Rittling, S. R. (2000). Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. British Journal of Cancer, 83(2), 156-163.
115. Nemoto, H., Rittling, S. R., Yoshitake, H., Furuya, K., Amagasa, T., Tsuji, K., et al. (2001). Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. Journal of Bone and Mineral Research, 16(4), 652-659.
116. Mukhopadhyay, R., & Price, J. E. (1999). Stable expression of Antisense osteopontin inhibits the growth of human breast cancer cells. Proceedings of the American Association for Cancer Research, 40(2), 448-449.
117. Adwan, H., Bauerle, T. J., & Berger, M. R. (2003). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy, 11(2), 109-120.
118. Gardner, H. A., Berse, B., & Senger, D. R. (1994). Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9(8), 2321-2326.
119. Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T., & Chambers, A. F. (1994). Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Research, 54(3), 832-837.
120. Tanabe, K. K., Ellis, L. M., & Saya, H. (1993). Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet, 341(8847), 725-726.
121. Stamenkovic, I., Aruffo, A., Amiot, M., & Seed, B. (1991). The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO Journal, 10(2), 343-348.
122. Matsumura, Y., & Tarin, D. (1992). Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340(8827), 1053-1058.
123. Tanabe, K. K., Stamenkovic, I., Cutler, M., & Takahashi, K. (1995). Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Annals of Surgery, 222(4), 493-501.
124. Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., & Tanabe, K. K. (1995). CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene, 11(11), 2223-2232.
125. Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342-348.
126. Lin, Y. H., & Yang-Yen, H. F. (2001). The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Journal of Biological Chemistry, 276(49), 46024-46030.
127. Hruska, K. A., Rolnick, F., Huskey, M., Alvarez, U., & Cheresh, D. (1995). Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology, 136(7), 2984-2992.
128. Chellaiah, M., & Hruska, K. (1996). Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Molecular Biology of the Cell, 7(5), 743-753.
129. Urquidi, V., Sloan, D., Kawai, K., Agarwal, D., Woodman, A. C., Tarin, D., et al. (2002). Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clinical Cancer Research, 8(1), 61-74.
130. Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., & Liotta, L. A. (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71(4), 1368-1383.
131. Murphy, G., & Gavrilovic, J. (1999). Proteolysis and cell migration: creating a path? Current Opinion in Cell Biology, 11(5), 614-621.
132. Philip, S., Bulbule, A., & Kundu, G. C. (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry, 276(48), 44926-44935.
133. Tuck, A. B., Hota, C., & Chambers, A. F. (2001). Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Research and Treatment, 70(3), 197-204.
134. Andreasen, P. A., Kjoller, L., Christensen, L., & Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer, 72(1), 1-22.
135. Fisher, J. L., Field, C. L., Zhou, H., Harris, T. L., Henderson, M. A., & Choong, P. F. (2000). Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Research and Treatment, 61(1), 1-12.
136. Philip, S., & Kundu, G. C. (2003). Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. Journal of Biological Chemistry, 278(16), 14487-14497.
137. Das, R., Mahabeleshwar, G. H., & Kundu, G. C. (2003). Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. Journal of Biological Chemistry, 278(31), 28593-28606.
138. Jain, S., Chakraborty, G., & Kundu, G. C. (2006). The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Research, 66(13), 6638-6648.
139. Rangswami, H., Bulbule, A., & Kundu, G. C. (2004). Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. Journal of Biological Chemistry, 279(37), 38921-38935.
140. Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134-1145.
141. Mi, Z., Oliver, T., Guo, H., Gao, C., & Kuo, P. C. (2007). Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Research, 67(9), 4088-4097.
142. Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews. Cancer, 3(5), 362-374.
143. Tuck, A. B., Hota, C., Wilson, S. M., & Chambers, A. F. (2003). Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22(8), 1198-1205.
144. Hayashi, C., Rittling, S., Hayata, T., Amagasa, T., Denhardt, D., Ezura, Y., et al. (2007). Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. Journal of Cellular Biochemistry, 101(4), 979-986.
145. Denhardt, D. T., & Chambers, A. F. (1994). Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. Journal of Cellular Biochemistry, 56(1), 48-51.
146. Gao, C., Guo, H., Wei, J., & Kuo, P. C. (2003). Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochemical and Biophysical Research Communications, 309(1), 120-125.
147. Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079-1086.
148. Gao, C., Guo, H., Mi, Z., Wai, P. Y., & Kuo, P. C. (2005). Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. Journal of Immunology, 175(1), 523-530.
149. Wai, P. Y., Guo, L., Gao, C., Mi, Z., Guo, H., & Kuo, P. C. (2006). Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery, 40(2), 132-140.
150. Scott, J. A., Weir, M. L., Wilson, S. M., Xuan, J. W., Chambers, A. F., & McCormack, D. G. (1998). Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology, 275(6), H2258-H2265.
151. Nagasaki, T., Ishimura, E., Koyama, H., Shioi, A., Jono, S., Inaba, M., et al. (1999). Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells-Possible role of osteopontin. Nephrology Dialysis Transplantation, 14(8), 1861-1866.
152. Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29(6), 15-18.
153. Hanrahan, V., Currie, M. J., Gunningham, S. P., Morrin, H. R., Scott, P. A., Robinson, B. A., et al. (2003). The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. Journal of Pathology, 200(2), 183-194.
154. Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., Imabun, S., Nakahara, M., et al. (2003). Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clinical Cancer Research, 9(2), 716-721.
155. Hirama, M., Takahashi, F., Takahashi, K., Akutagawa, S., Shimizu, K., Soma, S., et al. (2003). Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Letters, 198(1), 107-117.
156. Leali, D., Dell,, Era, P., Stabile, H., Sennino, B., Chambers, A. F., Naldini, A., et al. (2003). Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. Journal of Immunology, 171(2), 1085-1093.
157. Khan, S. A., Lopez-Chua, C. A., Zhang, J., Fisher, L. W., Sorensen, E. S., & Denhardt, D. T. (2002). Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. Journal of Cellular Biochemistry, 85(4), 728-736.
158. Malyankar, U. M., Hanson, R., Schwartz, S. M., Ridall, A. L., & Giachelli, C. M. (1999). Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells. Experimental Cell Research, 250(2), 535-547.
159. Zhang, Q., Wrana, J. L., & Sodek, J. (1992). Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a 'silent' second promoter. European Journal of Biochemistry, 207(2), 649-659.
160. Eferl, R., & Wagner, E. F. (2003). AP-1: A double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3(11), 859-868.
161. Deng, T., & Karin, M. (1993). JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes & Development, 7(3), 479-490.
162. Chiu, R., Angel, P., & Karin, M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell, 59(6), 979-986.
163. Wang, Z. Q., Grigoriadis, A. E., Mohle-Steinlein, U., & Wagner, E. F. (1991). A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras. EMBO Journal, 10(9), 2437-2450.
164. Grigoriadis, A. E., Schellander, K., Wang, Z. Q., & Wagner, E. F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. Journal of Cell Biology, 122(3), 685-701.
165. Young, M. R., Li, J. J., Rincon, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R., et al. (1999). Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proceedings of the National Academy of Sciences of the United States of America, 96(17), 9827-9832.
166. Jochum, W., David, J. P., Elliott, C., Wutz, A., Plenk Jr, H., Matsuo, K., et al. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Medicine, 6(9), 980-984.
167. Renault, M. A., Jalvy, S., Belloc, I., Pasquet, S., Sena, S., Olive, M., et al. (2003). AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circulation Research, 93(7), 674-681.
168. Kim, H. J., Lee, M. H., Kim, H. J., Shin, H. I., Choi, J. Y., & Ryoo, H. M. (2002). Okadaic acid stimulates osteopontin expression through de novo induction of AP-1. Journal of Cellular Biochemistry, 87(1), 93-102.
169. Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134-1145.
170. Wang, D., Yamamoto, S., Hijiya, N., Benveniste, E. N., & Gladson, C. L. (2000). Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA-protein interactions. Oncogene, 19(50), 5801-5809.
171. Kiermaier, A., Gawn, J. M., Desbarats, L., Saffrich, R., Ansorge, W., Farrell, P. J., et al. (1999). DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene, 18(51), 7200-7211.
172. Sirito, M., Lin, Q., Deng, J. M., Behringer, R. R., & Sawadogo, M. (1998). Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proceedings of the National Academy of Sciences of the United States of America, 95(7), 3758-3763.
173. Atchley, W. R., & Fitch, W. M. (1997). A natural classification of the basic helix-loop-helix class of transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 94(10), 5172-5176.
174. Jaiswal, A. S., & Narayan, S. (2001). Upstream stimulating factor-1 (USF1) and USF2 bind to and activate the promoter of the adenomatous polyposis coli (APC) tumor suppressor gene. Journal of Cellular Biochemistry, 81(2), 262-277.
175. Reisman, D., & Rotter, V. (1993). The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Research, 21(2), 345-350.
176. Bidder, M., Shao, J. S., Charlton-Kachigian, N., Loewy, A. P., Semenkovich, C. F., & Towler, D. A. (2002). Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. Journal of Biological Chemistry, 277(46), 44485-44496.
177. Tezuka, K., Denhardt, D. T., Rodan, G. A., & Harada, S. (1996). Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. Journal of Biological Chemistry, 271(37), 22713-22717.
178. Blobel, G. A., & Hanafusa, H. (1991). The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3′ untranslated region. Proceedings of the National Academy of Sciences of the United States of America, 88(4), 1162-1166.
179. Schonthal, A., Herrlich, P., Rahmsdorf, H. J., & Ponta, H. (1988). Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell, 54(3), 325-334.
180. Birchenall-Roberts, M. C., Ruscetti, F. W., Kasper, J., Lee, H. D., Friedman, R., Geiser, A., et al. (1990). Molecular and Cellular Biology, 10(9), 4978-4983.
181. Fujii, M., Shalloway, D., & Verma, I. M. (1989). Gene regulation by tyrosine kinases: Src protein activates various promoters, including c-fos. Molecular and Cellular Biology, 9(6), 2493-2499.
182. Apel, I., Yu, C. L., Wang, T., Dobry, C., Van Antwerp, M. E., Jove, R., et al. (1992). Regulation of the junB gene by v-src. Molecular and Cellular Biology, 12(8), 3356-3364.
183. Sato, H., Kita, M., & Seiki, M. (1993). v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. Journal of Biological Chemistry, 268(31), 23460-23468.
184. Lund, A. H., & van Lohuizen, M. (2002). RUNX: a trilogy of cancer genes. Cancer Cell, 1(3), 213-215.
185. Coffman, J. A. (2003). Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biology International, 27(4), 315-324.
186. Ito, Y., & Miyazono, K. (2003). RUNX transcription factors as key targets of TGF-beta superfamily signaling. Current Opinion in Genetics & Development, 13(1), 43-47.
187. Li, Q. L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X. Z., et al. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109(1), 113-124.
188. Speck, N. A., & Gilliland, D. G. (2002). Core-binding factors in haematopoiesis and leukaemia. Nature Reviews. Cancer, 2(7), 502-513.
189. Inman, C. K., & Shore, P. (2003). The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. Journal of Biological Chemistry, 278(49), 48684-48689.
190. Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89(5), 765-771.
191. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89(5), 755-764.
192. Sato, M., Morii, E., Komori, T., Kawahata, H., Sugimoto, M., Terai, K., et al. (1998). Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene, 17(12), 1517-1525.
193. Barnes, G. L., Javed, A., Waller, S. M., Kamal, M. H., Hebert, K. E., Hassan, M. Q., et al. (2003). Cancer Research, 63(10), 2631-2637.
194. Wai, P. Y., Mi, Z., Gao, C., Guo, H., Marroquin, C., & Kuo, P. C. (2006). Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. Journal of Biological Chemistry, 281(28), 18973-18982.
195. Lee, K. S., Kim, H. J., Li, Q. L., Chi, X. Z., Ueta, C., Komori, T., et al. (2000). Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Molecular and Cellular Biology, 20(23), 8783-92.
196. Hanai, J., Chen, L. F., Kanno, T., Ohtani-Fujita, N., Kim, W. Y., Guo, W. H., et al. (1999). Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. Journal of Biological Chemistry, 274(44), 31577-31582.
197. Shi, X., Bai, S., Li, L., & Cao, X. (2001). Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. Journal of Biological Chemistry, 276(1), 850-855.
198. Roberts, A. B., & Wakefield, L. M. (2003). The two faces of transforming growth factor beta in carcinogenesis.Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8621-8623.
199. Medrano, E. E. (2003). Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene, 22(20), 3123-3129.
200. Bello-DeOcampo, D., & Tindall, D. J. (2003). TGF-betal/Smad signaling in prostate cancer. Current Drugs Targets, 4(3), 197-207.
201. Guise, T. A., & Chirgwin, J. M. (2003). Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinica Ortopedica, 415(Suppl), S32-S38.
202. Kim, S. J., & Letterio, J. (2003). Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia, 17(9), 1731-1737.
203. Noda, M., Yoon, K., Prince, C. W., Butler, W. T., & Rodan, G. A. (1988). Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. Journal of Biological Chemistry, 263(27), 13916-13921.
204. Wrana, J. L., Kubota, T., Zhang, Q., Overall, C. M., Aubin, J. E., Butler, W. T., et al. (1991). Regulation of transformation-sensitive secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of SPARC (secreted acidic cysteine-rich protein). Biochemical Journal, 273(3), 523-531.
205. Cheifetz, S., Li, I. W., McCulloch, C. A., Sampath, K., & Sodek, J. (1996). Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-beta 1 on bone formation in vitro. Connective Tissue Research, 35(1-4), 71-78.
206. Hullinger, T. G., Pa, N. Q., Viswanatha, N. H. L., & Somerman, M. J. (2001). TGFbeta and BMP-2 activation of the OPN promoter: Roles of smad- and hox-binding elements. Experimental Cell Research, 262(1), 69-74.
207. Cui, J., Zhou, X., Liu, Y., Tang, Z., & Romeih, M. (2003). Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of Gastroenterology and Hepatology, 18(3), 280-287.
208. Bright-Thomas, R. M., & Hargest, R. (2003). APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. European Journal of Surgical Oncology, 29(2), 107-117.
209. El-Tanani, M., Barraclough, R., Wilkinson, M. C., & Rudland, P. S. (2001). Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Research, 61(14), 5619-5629.
210. Denhardt, D. T., Mistretta, D., Chambers, A. F., Krishna, S., Porter, J. F., Raghuram, S., et al. (2003). Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clinical & Experimental Metastasis, 20(1), 77-84.
211. Bos, J. L. (1989). Ras oncogenes in human cancer: A review. Cancer Research, 49(17), 4682-4689.
212. Chambers, A. F., Behrend, E. I., Wilson, S. M., & Denhardt, D. T. (1992). Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Research, 12(1), 43-47.
213. Guo, X., Zhang, Y. P., Mitchell, D. A., Denhardt, D. T., & Chambers, A. F. (1995). Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Molecular and Cellular Biology, 15(1), 476-487.
214. Morimoto, I., Sasaki, Y., Ishida, S., Imai, K., & Tokino, T. (2002). Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer, 33(3), 270-278.
215. Safe, S., & Abdelrahim, M. (2005). Sp transcription factor family and its role in cancer. European Journal of Cancer, 41(16), 2438-24348.
216. Takami, Y., Russell, M. B., Gao, C., Mi, Z., Guo, H., Mantyh, C. R., et al. (2007). Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery, 142(2), 163-169.
217. el-Deiry, W. S. (1998). Seminars in Cancer Biology, 8(5), 345-357.
218. Tokino, T., & Nakamura, Y. (2000). The role of p53-target genes in human cancer. Critical Reviews in Oncology/Hematology, 33(1), 1-6.
219. Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408(6810), 307-310.
220. Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., & Chen, X. (1999). p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene, 18(54), 7740-7747.
221. Craig, A. M., Bowde, N. G. T., Chambers, A. F., Spearman, M. A., Greenberg, A. H., Wright, J. A., et al. (1990). Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. International Journal of Cancer, 46(1), 133-137.
222. Chang, P. L., Tucker, M. A., Hicks, P. H., & Prince, C. W. (2002). Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. International Journal of Biochemistry & Cell Biology, 34(9), 1142-1151.
223. Manji, S. S., Ng, K. W., Martin, T. J., & Zhou, H. (1998). Transcriptional and posttranscriptional regulation of osteopontin gene expression in preosteoblasts by retinoic acid. Journal of Cellular Physiology, 176(1), 1-9.
224. Asaumi, S., Takemoto, M., Yokote, K., Ridall, A. L., Butler, W. T., Fujimoto, M., et al. (2003). Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. Journal of Diabetes and Its Complications, 17(1), 34-38.
225. Noda, M., Vogel, R. L., Craig, A. M., Prahl, J., DeLuca, H. F., & Denhardt, D. T. (1990). Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proceedings of the National Academy of Sciences of the United States of America, 87(24), 9995-9999.